3 results about "Clindamycin" patented technology

This invention discloses the application of L-lysine in improving the sensitivity of Vibrio alginolyticus to clindamycin. This invention discovers that the combined use of L-lysine and clindamycin can significantly increase reactive oxygen species within Vibrio alginolyticus, thereby increasing the amount of clindamycin entering the bacteria and ultimately leading to bacterial death. Therefore, L-lysine can improve bacterial sensitivity to clindamycin, thus overcoming the problem of bacterial resistance. The small molecule metabolite provided by this invention, when used in combination with clindamycin, can significantly enhance the bactericidal effect of clindamycin, exhibiting better efficacy, higher safety, and greater operability compared to existing methods that use clindamycin alone as an antibacterial drug.

Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w / w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

The invention relates to the technical field of drug carriers, in particular to a drug carrier for suppurative arthritis and a preparation method of the drug carrier. The drug carrier comprises liquid metal nanoparticles, a mesoporous material shell layer coating the liquid metal nanoparticles and a hyaluronic acid modification layer coating the mesoporous material shell layer, wherein liquid metal is gallium (Ga), gallium-indium alloy (GaIn), or ternary or multicomponent alloy containing gallium, indium and tin; the mesoporous material is at least one of mesoporous silica, mesoporous titanium dioxide and mesoporous carbon. The drug carrier can be used for loading different types of therapeutic agents (drugs) such as antibiotics (such as clindamycin), anti-inflammatory drugs and anti-tumor drugs, and the therapeutic agents can enter mesopores of the mesoporous material shell layer.